Vimarsana
Biggest News Aggregation in the World

Page 4 - Cell Viability News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cell Viability. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cell Viability Today - Breaking & Trending Today

Flow Cytometry Market worth $6.3 billion by 2026 - Exclusive Report by MarketsandMarkets™ - Vimarsana News

Flow Cytometry Market worth $6.3 billion by 2026 - Exclusive Report by MarketsandMarkets™

/PRNewswire/ -- According to the new market research report "Flow Cytometry Market by Product (Analyzer, Sorter, Reagents, Consumables, Software), Technology,...

Timosaponin AIII-based multifunctional liposomal delivery - Vimarsana News

Timosaponin AIII-based multifunctional liposomal delivery

Cholesterol is vulnerable to oxidation, the conventional liposomes including cholesterol in the formulation seem to be challenged.

FTY720 inhibits development of collagen-induced arthritis - Vimarsana News

FTY720 inhibits development of collagen-induced arthritis

Oral administration of fingolimod inhibits CD4+T lymphocyte recruitment and TNF-a-induced inflammation in a collagen-induced arthritis mouse model. Read more.

[Full text] Resiquimod for Prostate Cancer Treatment - Vimarsana News

[Full text] Resiquimod for Prostate Cancer Treatment

Purpose: With the advance of screening techniques, there is a growing number of low-risk or intermediate-risk prostate cancer (PCa) cases, remaining a serious threat to men’s health. To obtain better efficacy, a growing interest has been attracted to develop such emerging treatments as immunotherapy and focal therapy. However, few studies offer guidance on whether and how to combine these modalities against PCa. This study was designed to develop dual-functional nanoparticles (NPs) which combined photothermal therapy (PTT) with immunotherapy and determine the anti-tumor efficacy for PCa tre...

[Full text] Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K - Vimarsana News

[Full text] Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K

G, H) for both HT29DDP and HCT116-LOHP cells. The graphs of b, d, f. and h are the densitometry results of corresponding WB assays. Notes: *P 0.05; **P 0.01. Combination Treatment Promoted Apoptosis in Drug-Resistant Colon Cancer Cells We further analyzed the effect of combinational therapy on apoptosis of colon cancer cells. The results (Figure 5A–D) for HT29DDP and HCT116-LOHP cells, respectively) showed that the apoptotic rates of different treatment groups were higher than those of the untreated control group; the difference between PTX-16nM group and the control group was statisticall...